Medication info
Tugenonjeong 20/32 Milligrams

Tugenonjeong 20/32 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201702412 · Approved 2017.05.16

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and reduction of the risk of atherosclerosis and cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medication is for adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with use in patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Essential hypertension: The safety and efficacy of this medication in adolescents and children aged 18 years or younger have not been established. Heart failure: The safety and efficacy of this medication in adolescents and children aged 18 years or younger have not been established.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and reduction of the risk of atherosclerosis and cardiovascular disease

  • Essential hypertension
  • heart failure
  • hypercholesterolemia
  • dysbetalipoproteinemia
  • high blood pressure
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who require the simultaneous administration of two drugs, Candesartan Cilexetil and Rosuvastatin. First, Candesartan Cilexetil is mainly indicated for patients with essential hypertension and heart failure with reduced left ventricular function, particularly in cases where ACE inhibitor treatment is insufficient or not well tolerated. Meanwhile, Rosuvastatin helps improve cholesterol levels in patients with hypercholesterolemia and mixed dyslipidemia in conjunction with a dietary regimen. Additionally, it plays an adjunctive role in the treatment of patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia and is used to lower the risk of stroke, myocardial infarction, etc., in high-risk cardiovascular disease patients. By taking these two medications together, effective management of blood pressure and blood lipids is achieved, thus improving cardiovascular health.

How to take

Adult dose

This medication is for adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer, taking the patient's tolerability into account, up to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with use in patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Essential hypertension: The safety and efficacy of this medication in adolescents and children aged 18 years or younger have not been established. Heart failure: The safety and efficacy of this medication in adolescents and children aged 18 years or younger have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be administered in patients with hypersensitivity to it, severely impaired liver function, pregnant and nursing women, and patients with certain kidney diseases or myopathy. Elderly patients, patients with hyperkalemia, patients with compromised liver function, and patients with cardiovascular diseases should be monitored more closely when using this medication. If symptoms such as muscle pain or muscle weakness occur, consult a doctor immediately, and in severe cases, it may be necessary to discontinue this medication. This medication can affect liver and kidney function, so it is important to regularly check liver enzymes and kidney function through blood tests. When taken with other antihypertensives, diuretics, anticoagulants, etc., interactions may occur, so it is advisable to consult a doctor or pharmacist. Women who are pregnant or breastfeeding should not take this medication, and women who may become pregnant should use appropriate contraception. Its safety and efficacy have not been established for children, so it is not recommended for use. In case of overdose, symptoms such as hypotension and dizziness may appear, so it is essential to visit a medical institution immediately. Dizziness may occur while driving or operating machinery during the use of this medication, so caution is advised. Keep this medication out of reach of children, and avoid transferring it from the original container to another container.

Side effects

Headache, nasopharyngitis, local infection, fatigue, generalized pruritus, dermatitis, pruritus, joint stiffness, limb pain, photophobia, dyspepsia, hyperglycemia, hyponatremia, hand fracture, hypoglycemia, nephrolithiasis, cough, nausea, dizziness, postural dizziness, milia, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, hyperglycemia, hyponatremia, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, constipation, abdominal pain, diarrhea, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramp, gout, erectile dysfunction, paralysis, hypertonia, facial flush, facial edema, thirst, sleep disturbance, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, taste distortion, erectile dysfunction, angioedema, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbance, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular myasthenia, hypotension, hyperkalemia, renal impairment, increased creatinine, increased urea, increased potassium, decreased sodium, increased ALT, leukopenia, neutropenia, agranulocytosis, weakness, hunger, cold sweat, hand tremors, decreased concentration, convulsion, altered consciousness, pneumonia, intestinal vascular edema, jaundice, hepatitis, rash, urticaria, angioedema, myalgia, weakness, elevated creatine kinase, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, dizziness, postural dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best stored at room temperature, i.e., between 1°C and 30°C. Proper storage will help maintain the effectiveness of the medication for a longer time.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.